Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression

Overexpression of EZH2 is frequently linked to the advanced and metastatic stage of cancers. The mechanisms of its oncogenic function can be context specific, and may vary depending on the protein complexes that EZH2 interacts with. To identify novel transcriptional collaborators of EZH2 in cancers, a computational approach was developed that integrates protein–DNA binding data, cell perturbation gene expression data, and compendiums of tumor expression profiles. This holistic approach identified E2F1, a known mediator of the Rb tumor suppressor, as a transcriptional collaborator of EZH2 in castration-resistant prostate cancer. Subsequent analysis and experimental validation found EZH2 and E2F1 cobind to a subset of chromatin sites lacking H3K27 trimethylation, and activate genes that are critical for prostate cancer progression. The collaboration of EZH2 and E2F1 in transcriptional regulation is also observed in diffuse large B-cell lymphoma cell lines, where activation of the transcriptional network is concordant with the cellular response to the EZH2 inhibitor. Implications: The direct collaboration between EZH2 and Rb/E2F1 pathway provides an innovative mechanism underlying the cascade of tumor progression, and lays the foundation for the development of new anticancer targets/strategies. Mol Cancer Res; 14(2); 163–72. ©2015 AACR.

[1]  Luca Pinello,et al.  Developmental control of polycomb subunit composition by GATA factors mediates a switch to non-canonical functions. , 2015, Molecular cell.

[2]  Li-xiang Xue,et al.  EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma , 2014, Molecular Cancer Research.

[3]  Mariano J. Alvarez,et al.  Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy. , 2014, Cancer cell.

[4]  A. Singh,et al.  EZH2: Not EZHY (Easy) to Deal , 2014, Molecular Cancer Research.

[5]  L. Ferrarini,et al.  Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. , 2013, The Journal of clinical investigation.

[6]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[7]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[8]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[9]  J. Edwards,et al.  Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients , 2012, British Journal of Cancer.

[10]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[11]  P. Atadja,et al.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.

[12]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[13]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[14]  Stefano Monti,et al.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.

[15]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[16]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[17]  Tao Liu,et al.  CistromeMap: a knowledgebase and web server for ChIP-Seq and DNase-Seq studies in mouse and human , 2012, Bioinform..

[18]  H. Hock.  A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.

[19]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[20]  David Engelmann,et al.  The dark side of E2F1: in transit beyond apoptosis. , 2012, Cancer research.

[21]  Sven Laur,et al.  Robust rank aggregation for gene list integration and meta-analysis , 2012, Bioinform..

[22]  M. Hung,et al.  The role of EZH2 in tumour progression , 2011, British Journal of Cancer.

[23]  Hui Liu,et al.  AnimalTFDB: a comprehensive animal transcription factor database , 2011, Nucleic Acids Res..

[24]  S. Orkin,et al.  PRC2 directly methylates GATA4 and represses its transcriptional activity. , 2012, Genes & development.

[25]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[26]  P. Nelson,et al.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. , 2010, The Journal of clinical investigation.

[27]  E. Brambilla,et al.  Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers , 2010, Oncogene.

[28]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[29]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[30]  Qiang Yu,et al.  Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression , 2010, Cell Death and Differentiation.

[31]  Ken Chen,et al.  VarScan: variant detection in massively parallel sequencing of individual and pooled samples , 2009, Bioinform..

[32]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[33]  Juan M. Vaquerizas,et al.  A census of human transcription factors: function, expression and evolution , 2009, Nature Reviews Genetics.

[34]  Lior Pachter,et al.  Sequence Analysis , 2020, Definitions.

[35]  J. Pollack,et al.  MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. , 2008, Blood.

[36]  R. Chakrabarti,et al.  Androgen regulates Cdc6 transcription through interactions between androgen receptor and E2F transcription factor in prostate cancer cells. , 2008, Biochimica et biophysica acta.

[37]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[38]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[39]  Jing Liang,et al.  Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells , 2007, Molecular and Cellular Biology.

[40]  Stephanie Daignault,et al.  Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. , 2006, Cancer research.

[41]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[42]  C. Maier,et al.  Mutation screen and association study of EZH2 as a susceptibility gene for aggressive prostate cancer , 2005, The Prostate.

[43]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Kathryn A. O’Donnell,et al.  c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.

[45]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[46]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[47]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[48]  Yihong Ma,et al.  Identification of novel E2F1-regulated genes by microarray. , 2002, Archives of biochemistry and biophysics.

[49]  Martin R. Schneider,et al.  Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system , 1999, British Journal of Cancer.